Stocks Health care ARDX
NASDAQ · Health careArdelyx, Inc. (ARDX)
Ardelyx, Inc. brought in $468.2M of revenue over the twelve months to September 30, 2026, up 17.6% from a year earlier. It posted a net loss of $55.5M. In fiscal 2025 capital spending exceeded operating cash flow by $44M. At September 30, 2026 it held $46.3M in cash against $252.4M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 3, 2026.
Key facts about Ardelyx, Inc.
- Net worth
- Ardelyx, Inc. has a market value (market cap) of $730.1M at the latest share price, and shareholders' equity of $164M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $407.3M (+22.1% year on year), with a net loss of $61.6M. Over the 12 months to September 30, 2026: revenue $468.2M, net loss $55.5M.
- Cash flow
- In fiscal 2025 operations used $42.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 3, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Ardelyx, Inc.'s next report is expected around January 7, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Ardelyx, Inc. does
Ardelyx, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ARDX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $407.3M | -$61.6M | -$0.26 | -$44M |
| 2024 | $333.6M | -$39.1M | -$0.17 | -$45.8M |
| 2023 | $124.5M | -$66.1M | -$0.30 | -$90.1M |
| 2022 | $52.2M | -$67.2M | -$0.42 | -$70.1M |
| 2021 | $10.1M | -$158.2M | -$1.52 | -$154.4M |
| 2020 | $7.6M | -$94.3M | -$1.05 | -$81.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ARDX ranks in Health care
Latest SEC filings
What Ardelyx, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 16% to $127.7M versus the same quarter last year; diluted EPS $0.00 versus $0.00.
- November 3, 2026
- August 17, 2026Other event 8-K
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 11, 2026Passive stake changed SCHEDULE 13G/A
- August 10, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 24% to $120.9M versus the same quarter last year; diluted EPS -$0.07 versus -$0.08.
- August 6, 2026
- July 2, 2026New debt 8-K
- June 17, 2026
Insider trades
What the people running Ardelyx, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $486.2K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 21, 2026 | Bishop John ESee Remarks | Sold | 17,281 | $66.7K |
| August 21, 2026 | Bishop John ESee Remarks | Sold | 2,469 | $9.5K |
| August 21, 2026 | Raab MichaelPresident & CEO, Director | Sold | 15,009 | $57.9K |
| August 21, 2026 | Raab MichaelPresident & CEO, Director | Sold | 15,976 | $61.6K |
| August 21, 2026 | Raab MichaelPresident & CEO, Director | Sold | 8,411 | $32.4K |
| August 21, 2026 | Raab MichaelPresident & CEO, Director | Sold | 19,178 | $74K |
| August 21, 2026 | Williams Laura AChief Patient Officer | Sold | 3,486 | $13.4K |
| August 21, 2026 | Williams Laura AChief Patient Officer | Sold | 3,089 | $11.9K |
Who owns ARDX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Rubric Capital Management LP13G, passive with 1 related filers | 6.56% | August 14, 2026 |
| Millennium Management LLC13G, passive with 3 related filers | 5.7% | August 11, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 249 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 23,504,630 | +2,340,498 |
| Rubric Capital Management LP | 16,202,700 | +14,341,804 |
| Millennium Management LLC | 13,900,773 | -3,941,597 |
| State Street Corp | 13,356,128 | -248,179 |
| Vanguard Capital Management LLC | 10,471,494 | +105,982 |
| Nomura Asset Management International Inc. | 9,546,732 | +1,377,363 |
| Vanguard Portfolio Management LLC | 8,026,774 | +1,365,081 |
| Geode Capital Management, LLC | 6,401,736 | +394,281 |
| Jupiter Topco LLC | 5,302,311 | new |
| Two Sigma Investments, LP | 5,209,823 | +935,780 |
| Nuveen, LLC | 3,997,099 | -1,237,584 |
| Goldman Sachs Group Inc | 3,685,034 | +468,824 |
| AIGH Capital Management LLC | 3,200,000 | new |
| Morgan Stanley | 2,389,546 | +680,573 |
| Aqr Capital Management LLC | 2,316,220 | -123,230 |
| Northern Trust Corp | 2,280,143 | +209,096 |
| Rock Springs Capital Management LP | 2,241,769 | -57,704 |
| Charles Schwab Investment Management Inc | 2,211,760 | +97,662 |
| Bank of America Corp | 2,163,500 | -173,494 |
| Qube Research & Technologies Ltd | 2,090,675 | -344,873 |
Insiders
16 insiders reported holding 8,595,488 shares in total, about $25.2M at the last price.
| Holder | Shares |
|---|---|
| Mott David MDirector | 3,349,655 |
| Raab MichaelPresident & CEO, Director | 1,619,792 |
| Rodgers Richard JDirector | 439,998 |
| Foster Eric DuaneChief Commercial Officer | 409,410 |
| Williams Laura AChief Patient Officer | 367,456 |
| Kelliher MikeChief Business Officer | 349,660 |
| Bertrand William C JRDirector | 329,507 |
| Bishop John ESee Remarks | 317,095 |
| Grammer Elizabeth ASee Remarks | 299,895 |
| Brady James ParkerChief Human Resources Officer | 245,930 |
Questions about ARDX
What does Ardelyx, Inc. do?
Ardelyx, Inc. is a company in the Health care sector, listed on NASDAQ as ARDX. Its shares trade on NASDAQ under the ticker ARDX.
What is Ardelyx, Inc.'s net worth?
Ardelyx, Inc. has a market value (market cap) of $730.1M at the latest share price, and shareholders' equity of $164M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Ardelyx, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $55.5M on revenue of $468.2M.
How much revenue does Ardelyx, Inc. make?
Over the twelve months to September 30, 2026 Ardelyx, Inc. reported revenue of $468.2M. That is 17.6% more than a year earlier.
When did Ardelyx, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 3, 2026. It covers the period to September 30, 2026.
When is Ardelyx, Inc.'s next earnings report?
Ardelyx, Inc.'s next report is expected around January 7, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ARDX with
Follow ARDX
Get an email when Ardelyx, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Ardelyx, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.